Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Avatar

Discrepancy Between Real World vs. Clinical Trial Data in Relapsed/Refractory Multiple Myeloma Treatment

By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Meletios Dimopoulos
October 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

10:37
Amgen Oncology

Multiple Myeloma: Importance of Proteasome Inhibition at First Relapse

Feat. J. Abbas

Featured Video

10:37
Amgen Oncology

Multiple Myeloma: Importance of Proteasome Inhibition at First Relapse

Feat. J. Abbas

Related Content

AUTOPLAY
Moffitt Cancer Center

16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Sat, Jan 18, 2020
The University of Kansas Cancer Center

KU ASH 2019 Review: Current Updates in Hematologic Diseases

Sat, Jan 18, 2020
Indy Hematology Review

17th Indy Hematology Review

Sat, Mar 21, 2020
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Fri, Feb 7, 2020
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah
08:15
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
09:49
Nina Shah

Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Maint...

06:12
Indy Hematology Review

Targeting Mutations in Myeloma with Venetoclax and Development of the Fi...

Feat. K. Anderson
10:30
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Next Questions in Myeloma: Biology, Smoldering Myeloma, High-risk, MRD, ...

Feat. S. Jagannath
19:41
Peter Voorhees

Approach to the Patient with Refractory & Multiple Relapsed Multiple Mye...

10:17
Amgen Oncology

Multiple Myeloma: Use of Proteasome Inhibitor at First Relapse-A Case Study

Feat. H. Kaya
15:02
Krina Patel

Clinical Trials in Myeloma in 2018

15:11
Ajay Nooka

Early Relapse: Choosing Among Different Second Line Regimens in Myeloma

10:37
Amgen Oncology

Multiple Myeloma: Importance of Proteasome Inhibition at First Relapse

Feat. J. Abbas
16:22
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

FDA Approves Selinexor for Refractory Multiple Myeloma, STORM Study

Feat. S. Jagannath
12:32
Indy Hematology Review

What's New in Immunotherapy and Genomics in Multiple Myeloma?

Feat. K. Anderson
15:10
Krina Patel

Developing CAR T-cells in Multiple Myeloma

15:47
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Myeloma State of the Art Update: Bone Disease, MRD Assessment, How to Ma...

Feat. S. Lonial
09:01
Maria-Victoria Mateos

FDA Approves Once-Weekly Carfilzomib Regimen for Myeloma

15:31
Parameswaran Hari

Refractory and Relapsing Myeloma - When to Treat and Options Available

14:43
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

What Will The Future Hold for Myeloma Treatment CARTs vs BiTES?

Feat. R. Orlowski
17:58
City of Hope

Should Everyone Receive Monoclonal Antibodies at First Myeloma Relapse? No!

Feat. J. Mikhael
06:23
Parameswaran Hari

Treating Refractory & Relapsing Myeloma: Current Trends and Recommendati...

17:47
Dana-Farber Cancer Institute

Relapse Refractory Myeloma and Novel Treatments

Feat. N. Raje